Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
JW got another marketing approval for itopride
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 17, 2014 02:50:46
JW Life Sciences got marketing approval for Pregaton (itopride) on October 14.

Pregaton has the same active ingredient as JW Choongwae’s Ganaton. JW Life Sciences is a subsidiary of JW Choongwae.

JW Choongwae Shinyak, another subsidiary of JW Choongwae, also has Easys that contains itopride. In other words, JW has its triplets, Ganaton, Easys, and Pregaton under one roof.

Ganaton went off patent in 2010. There are many generic versions on the market. Easys’s sales have been insignificant.

Industry experts point that some companies manufacture their twin drug to defend their market shares once their brand-name drugs go off patent.

As the listing price of a brand-name drug is cut to a half once the first generic version enters the market in South Korea, the twin drug doesn’t get into the market before the patent expiration of the original brand-name drug.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com